英夫利昔单抗单药治疗巨细胞动脉炎。 - Suppr

Infliximab as monotherapy in giant cell arteritis.

作者信息

Uthman Imad, Kanj Nadim, Atweh Samir

出版信息

Clin Rheumatol. 2006 Feb;25(1):109-10. doi: 10.1007/s10067-005-1115-8. Epub 2005 May 18.

DOI:10.1007/s10067-005-1115-8

PMID:15902519

Abstract

摘要

相似文献

Infliximab as monotherapy in giant cell arteritis.

Clin Rheumatol. 2006 Feb;25(1):109-10. doi: 10.1007/s10067-005-1115-8. Epub 2005 May 18.

Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.

Rheumatology (Oxford). 2002 Mar;41(3):347-9. doi: 10.1093/rheumatology/41.3.347.

Infliximab efficiency and failure.

Ann Rheum Dis. 2004 Jun;63(6):751-2; author reply 752.

Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.

Ann Rheum Dis. 2003 Nov;62(11):1116. doi: 10.1136/ard.62.11.1116.

Summaries for patients. Adding infliximab to the treatment regimen for giant cell arteritis.

Ann Intern Med. 2007 May 1;146(9):I12. doi: 10.7326/0003-4819-146-9-200705010-00001.

Tumor necrosis factor blocking agents in polymyalgia rheumatica and giant cell arteritis.

Ann Intern Med. 2008 Jan 15;148(2):167-8; author reply 168. doi: 10.7326/0003-4819-148-2-200801150-00018.

Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?

Ann Intern Med. 2007 May 1;146(9):674-6. doi: 10.7326/0003-4819-146-9-200705010-00011.

[First scientific meeting of CRI (Rheumatism and Inflammation Club) under the patronage of FNSIM (French National Society of Internal Medicine) and FSR(French Society of Rheumatology) Paris, May 4, 2002].

Rev Med Interne. 2002 Oct;23(10):805-7. doi: 10.1016/s0248-8663(02)00706-3.

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Ann Intern Med. 2007 May 1;146(9):621-30. doi: 10.7326/0003-4819-146-9-200705010-00004.

Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.

Arthritis Rheum. 2001 Dec;44(12):2933-5. doi: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y.

引用本文的文献

Current developments in the diagnosis and treatment of giant cell arteritis.

Front Med (Lausanne). 2022 Dec 13;9:1066503. doi: 10.3389/fmed.2022.1066503. eCollection 2022.

Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Clin Rev Allergy Immunol. 2018 Apr;54(2):244-260. doi: 10.1007/s12016-017-8643-2.

Biologic Therapy for the Treatment of Giant Cell Arteritis.

Neuroophthalmology. 2014 Apr 2;38(3):107-112. doi: 10.3109/01658107.2014.883635. eCollection 2014.

New indications for biological therapies.

Intern Emerg Med. 2011 Oct;6 Suppl 1:1-9. doi: 10.1007/s11739-011-0667-7.

The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.

Rheumatol Int. 2009 Aug;29(10):1255-7. doi: 10.1007/s00296-008-0816-0. Epub 2008 Dec 4.

The treatment of giant cell arteritis.

Rev Neurol Dis. 2008 Summer;5(3):140-52.

Diagnosis and treatment of giant cell arteritis.

Drugs Aging. 2008;25(4):281-97. doi: 10.2165/00002512-200825040-00002.

[Infliximab is ineffective against giant cell arteritis and polymyalgia rheumatica].

Z Rheumatol. 2007 Oct;66(6):536-7. doi: 10.1007/s00393-007-0210-4.

本文引用的文献

The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon.

Semin Arthritis Rheum. 2004 Jun;33(6):422-3. doi: 10.1016/j.semarthrit.2003.12.005.

Infliximab efficiency and failure.

Ann Rheum Dis. 2004 Jun;63(6):751-2; author reply 752.

Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Rheumatology (Oxford). 2004 Mar;43(3):294-301. doi: 10.1093/rheumatology/keh058. Epub 2003 Dec 16.

Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.

Ann Rheum Dis. 2003 Nov;62(11):1116. doi: 10.1136/ard.62.11.1116.

Giant-cell arteritis and polymyalgia rheumatica.

Ann Intern Med. 2003 Sep 16;139(6):505-15. doi: 10.7326/0003-4819-139-6-200309160-00015.

A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.

Arthritis Rheum. 2002 Feb;47(1):29-35. doi: 10.1002/art1.10161.

Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.

Arthritis Rheum. 2001 Dec;44(12):2933-5. doi: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y.

Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.

Arthritis Rheum. 2000 May;43(5):1041-8. doi: 10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7.

Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis.

Rheumatol Int. 1997;17(3):113-8. doi: 10.1007/s002960050019.

Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients.

J Rheumatol. 1994 Jul;21(7):1283-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Infliximab as monotherapy in giant cell arteritis.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Infliximab as monotherapy in giant cell arteritis.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献